| 1 |
34996412 | Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. | 2022 Jan 8 |
1 |
| 2 |
33462346 | Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. | 2021 Apr |
2 |
| 3 |
32778670 | Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. | 2020 Aug 10 |
1 |
| 4 |
33235483 | Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments. | 2020 |
1 |
| 5 |
30339275 | The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. | 2019 Apr |
1 |
| 6 |
29487697 | DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. | 2018 Jan 30 |
1 |
| 7 |
29861877 | SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. | 2018 May 18 |
2 |
| 8 |
30075835 | Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. | 2018 Jul |
1 |
| 9 |
30498448 | Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma. | 2018 |
2 |
| 10 |
27641154 | Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. | 2017 Apr |
1 |
| 11 |
28262261 | Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics. | 2017 Apr |
2 |
| 12 |
28395759 | A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. | 2017 Feb |
2 |
| 13 |
28637434 | Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. | 2017 Jun 20 |
3 |
| 14 |
27072236 | Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer. | 2016 Jan-Mar |
1 |
| 15 |
25782327 | DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. | 2015 Sep |
2 |
| 16 |
25783977 | Costs and effectiveness of genomic testing in the management of colorectal cancer. | 2015 Mar |
1 |
| 17 |
20513938 | Pharmacogenetic application in personalized cancer treatment. | 2010 Apr |
1 |
| 18 |
20637356 | [Recent developments of pharmacogenomics in the treatment of colorectal cancers]. | 2010 Jul |
1 |
| 19 |
19457654 | Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. | 2009 Jul |
1 |
| 20 |
19262706 | Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. | 2007 Sep |
2 |
| 21 |
16251201 | Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. | 2006 Jan |
1 |
| 22 |
17163168 | Pharmacogenomics and colorectal cancer. | 2006 |
1 |